title: Design and fungicidal activity of mucoadhesive lactoferrin tablets for the treatment of oropharyngeal candidosis.
abstract: Lactoferrin (Lf) is a potential drug candidate for the treatment of oropharyngeal Candida infections. However, for an effective therapeutic treatment an appropriate dosage form is required. Therefore a mucoadhesive tablet for buccal application was developed. Tablets of sufficient strength could be produced on high speed tabletting machines, but they could only be obtained when the protein contained at least 7% moisture. The tablet contained sodium alginate both for its release-controlling properties as well as for its mucoadhesive properties. Furthermore, phosphate buffer was added to keep the pH of the saliva in the mouth within the range of 6.5 to 7.5. In this pH range, Lf has shown to have its highest activity against Candida growth inhibition. The tablet formulation containing Lf had the same antifungal properties as compared with Lf alone, because in most cases identical inhibitory concentrations were observed against several clinical isolates of Candida albicans and Candida glabrata. In human volunteers the tablets, containing 250 mg Lf and placed in each pouch, were able to keep the Lf concentration in the saliva at effective levels for at least 2 hr, while the pH of the saliva remained within the desired range. We concluded that the developed mucoadhesive tablet can improve the therapeutic efficacy of Lf and that it is suitable for further clinical research.
authors.affiliation: Department of Pharmacokinetics and Drug Delivery, University of Groningen, Groningen, The Netherlands.
authors.forename: Mirjam E
authors.initials: ME
authors.lastname: Kuipers
authors.forename: Jannet
authors.initials: J
authors.lastname: Heegsma
authors.forename: Hester I
authors.initials: HI
authors.lastname: Bakker
authors.forename: Dick K F
authors.initials: DK
authors.lastname: Meijer
authors.forename: Pieter J
authors.initials: PJ
authors.lastname: Swart
authors.forename: Erik W
authors.initials: EW
authors.lastname: Frijlink
authors.forename: Anco C
authors.initials: AC
authors.lastname: Eissens
authors.forename: Hilly G
authors.initials: HG
authors.lastname: de Vries-Hospers
authors.forename: Jeroen J M
authors.initials: JJ
authors.lastname: van den Berg
mesh_terms: D000268:Adhesiveness; D000278:Administration, Buccal; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000254:growth & development; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000382:microbiology; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D015195:Drug Design; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007781:Lactoferrin / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D009061:Mouth Mucosa; D012463:Saliva / Q000737:chemistry; D013607:Tablets
chemical_list: D000935:Antifungal Agents; D003692:Delayed-Action Preparations; D013607:Tablets; D007781:Lactoferrin